

USPN 10/607,706
Response to Office Action
July 23, 2007

Amgen Inc.
Docket No. 97-04D3
(A-933-E)

AMENDMENTS TO THE CLAIMS

This listing of the claims will replace all prior versions and listings of claims in this application.

Claims

1.-18. (canceled)

19. (original) An isolated polynucleotide molecule encoding an isolated peptide, wherein the peptide is selected from the group consisting of:

- a) residues 2 to 18 of SEQ ID NO:11;
- b) residues 2 to 14 of SEQ ID NO:11;
- c) residues 3 to 18 of SEQ ID NO:11;
- d) residues 3 to 14 of SEQ ID NO:11;
- e) residues 4 to 18 of SEQ ID NO:11;
- f) residues 4 to 14 of SEQ ID NO:11;
- g) residues 1 to 11 of SEQ ID NO:11;
- h) residues 1 to 10 of SEQ ID NO:11; and
- i) residues 2 to 11 of SEQ ID NO:11.

20.-22. (canceled)

23. (new) The polynucleotide of claim 19, wherein the polynucleotide is a DNA molecule.

24. (new) The polynucleotide of claim 19, wherein the polynucleotide is an RNA molecule.

25. (new) An expression vector comprising the polynucleotide molecule of claim 19.

26. (new) A host cell comprising the expression vector of claim 25, whereby the cell expresses the peptide encoded by the polynucleotide.

USSN 10/607,706
Response to Office Action
July 23, 2007

Amgen Inc.
Docket No. 97-04D3
(A-933-E)

27. (new) A method of producing a peptide, comprising culturing the host cell of claim 26 under conditions suitable for expressing the peptide, wherein the peptide is selected from the group consisting of residues 2 to 18 of SEQ ID NO:11; residues 2 to 14 of SEQ ID NO:11; residues 3 to 18 of SEQ ID NO:11; residues 3 to 14 of SEQ ID NO:11; residues 4 to 18 of SEQ ID NO:11; residues 4 to 14 of SEQ ID NO:11; residues 1 to 11 of SEQ ID NO:11; residues 1 to 10 of SEQ ID NO:11; and residues 2 to 11 of SEQ ID NO:11